Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

More news

Drug interactions and pharmacokinetics news selected from other sources

  • Viral Load Reductions Persist With Less Efavirenz for HIV

    The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

    07 November 2014 | Medscape (requires free registration)
  • Change to recommended regimen for post-exposure prophylaxis (PEP)

    The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

    11 September 2014 | Expert Advisory Group on AIDS (EAGA)
  • Dosage of HIV drug may be ineffective for half of African-Americans

    Many African-Americans may not be getting effective doses of the HIV drug maraviroc. The initial dosing studies included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body, resulting in higher concentrations of the drug in the blood. The current study shows that people with maximum levels of the protein CYP3A5 -- including nearly half of African-Americans -- end up with lower levels of maraviroc in their bodies.

    28 August 2014 | Eurekalert Medicine & Health
  • Opioid Therapy No Bar to Novel HCV Drugs

    People on opioid substitution therapy for drug addiction can be safely and effectively treated for hepatitis C (HCV) with an investigational combination of medications, researchers said here.

    24 July 2014 | MedPage Today
  • Advice on Best ART Regimen for Patients Taking Cancer Therapy

    Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.

    25 June 2014 | International AIDS Society
  • In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

    Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

    02 June 2014 | Medscape
  • No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

    Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

    29 May 2014 | NATAP
  • Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals

    Calcium supplements taken with dolutegravir between meals lowered dolutegravir exposure by one third. Iron supplements with dolutegravir between meals approximately halved dolutegravir exposure. Supplements did not have this effect when taken with dolutegravir with a meal, or when dolutegravir was taken 2 hours before the supplement.

    24 May 2014 | NATAP
  • Better Late Than Never: Efavirenz Dose Optimization

    After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

    03 April 2014 | Treatment Action Group
  • Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

    The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable.

    31 March 2014 | Morbidity and Mortality Weekly Report
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.